IL27RA is a promising key target for statins in treating hyperlipidemia

Statins are widely used in the treatment of hyperlipidemia; however, their specific mechanisms of action remain incompletely understood. To identify key therapeutic targets, we integrated differential expression analysis with machine learning and identified IL27RA as a pivotal candidate. IL27RA expression was significantly upregulated in atorvastatin-treated hyperlipidemia patients compared to healthy controls but decreased following statin intervention. Functional enrichment analysis revealed its association with immune-related pathways, and consistent with this, immune infiltration analysis showed significant correlations between IL27RA expression and the abundance of Th1 and plasmacytoid dendritic cells. Molecular docking and dynamics simulations further confirmed stable binding between IL27RA and atorvastatin. Collectively, these results establish IL27RA as a key therapeutic target for statins in hyperlipidemia and highlight its role in modulating the immune microenvironment.

The online version contains supplementary material available at 10.1007/s13205-025-04668-w.